title: Serotonin syndrome after concomitant treatment with linezolid and citalopram.
abstract: Linezolid, a new synthetic antimicrobial, is an important weapon against methicillin-resistant Staphylococcus aureus (MRSA). Although there are reports of serotonin syndrome developing after concomitant use of linezolid and the selective serotonin reuptake inhibitor paroxitene, this report concerns a patient receiving citalopram who developed thrombocytopenia, serotonin syndrome, and lactic acidosis and died following long-term linezolid therapy.
authors.affiliation: Division of Orthopaedic Surgery, Geneva University Hospital, Geneva, Switzerland. louis.bernard@hcuge.ch
authors.forename: L
authors.initials: L
authors.lastname: Bernard
authors.forename: R
authors.initials: R
authors.lastname: Stern
authors.forename: D
authors.initials: D
authors.lastname: Lew
authors.forename: P
authors.initials: P
authors.lastname: Hoffmeyer
mesh_terms: D000081:Acetamides / Q000009:adverse effects*; D000140:Acidosis, Lactic / Q000139:chemically induced; D015283:Citalopram / Q000009:adverse effects*; D004338:Drug Combinations; D006801:Humans; D000069349:Linezolid; D023303:Oxazolidinones / Q000009:adverse effects*; D011500:Protein Synthesis Inhibitors / Q000009:adverse effects; D020230:Serotonin Syndrome / Q000139:chemically induced*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000081:Acetamides; D015283:Citalopram; D004338:Drug Combinations; D000069349:Linezolid; D023303:Oxazolidinones; D011500:Protein Synthesis Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors